Neil John Parrott (Neil Parrott)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 26

Top Topics

Urinary Tract Infection

Machine Learning

Low Birth Weight

Top Venues

CPT: pharmacometrics & systems pharmacology

Molecular pharmaceutics

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Kenichi Umehara, Neil John Parrott, Emilie Schindler, Valentin Legras, Georgina Meneses-Lorente
PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co-Administered with CYP3A4 Inhibitors. Clinical pharmacology and therapeutics (2024)
Nicoló Milani, Neil John Parrott, Aleksandra Galetin, Stephen Fowler, Michael Gertz
In silico modeling and simulation of organ-on-a-chip systems to support data analysis and a priori experimental design. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Christopher A Darlow, Neil John Parrott, Richard Wilson Peck, William W Hope
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Nicoló Milani, Neil John Parrott, Aleksandra Galetin, Stephen Fowler, Michael Gertz
In silico modeling and simulation of organ-on-a-chip systems to support data analysis and a priori experimental design. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Christopher A Darlow, Neil John Parrott, Richard Wilson Peck, William W Hope
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Christopher A Darlow, Neil John Parrott, Richard Wilson Peck, William W Hope
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Nicoló Milani, Neil John Parrott, Aleksandra Galetin, Stephen Fowler, Michael Gertz
In silico modeling and simulation of organ-on-a-chip systems to support data analysis and a priori experimental design. CPT: pharmacometrics & systems pharmacology (2024)
Christopher A Darlow, Neil John Parrott, Richard Wilson Peck, William W Hope
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Christopher A Darlow, Neil John Parrott, Richard Wilson Peck, William W Hope
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Nicoló Milani, Neil John Parrott, Aleksandra Galetin, Stephen Fowler, Michael Gertz
In silico modeling and simulation of organ-on-a-chip systems to support data analysis and a priori experimental design. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Nicoló Milani, Neil John Parrott, Aleksandra Galetin, Stephen Fowler, Michael Gertz
In silico modeling and simulation of organ-on-a-chip systems to support data analysis and a priori experimental design. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Nicoló Milani, Neil John Parrott, Aleksandra Galetin, Stephen Fowler, Michael Gertz
In silico modeling and simulation of organ-on-a-chip systems to support data analysis and a priori experimental design. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Christopher A Darlow, Neil John Parrott, Richard Wilson Peck, William W Hope
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Christopher A Darlow, Neil John Parrott, Richard Wilson Peck, William W Hope
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Neil John Parrott, Nassim Djebli, Felix Jaminion, David Carlile, Elena Guerini, Amaury O'Jeanson
Evaluation of the Potential Impact on Pharmacokinetics of Various Cytochrome P450 Substrates of increasing IL-6 Levels following administration of the T-cell bispecific engager Glofitamab. CPT: pharmacometrics & systems pharmacology (2023)
Christopher A Darlow, Neil John Parrott, Richard Wilson Peck, William W Hope
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. CPT: pharmacometrics & systems pharmacology (2023)
Nenad Manevski, Kenichi Umehara, Neil John Parrott
Drug Design and Success of Prospective Mouse In Vitro-In Vivo Extrapolation (IVIVE) for Predictions of Plasma Clearance (CL p ) from Hepatocyte Intrinsic Clearance (CL int ). Molecular pharmaceutics (2023)
Tejashree Belubbi, Davide Bassani, Cordula Stillhart, Neil John Parrott
Physiologically Based Biopharmaceutics Modeling of Food Effect for Basmisanil: A Retrospective Case Study of the Utility for Formulation Bridging. Pharmaceutics 15 (1) (2023)
Christopher A Darlow, Neil John Parrott, Richard Wilson Peck, William Hope
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment. CPT: pharmacometrics & systems pharmacology (2023)
Matthias Van der Veken, Michael Aertsen, Joachim Brouwers, Cordula Stillhart, Neil John Parrott, Patrick Augustijns
Correction: Van der Veken et al. Gastrointestinal Fluid Volumes in Pediatrics: A Retrospective MRI Study. Pharmaceutics 2022, 14 , 1935. Pharmaceutics 15 (9) (2023)
Matthias Van der Veken, Joachim Brouwers, Agustos Cetin Ozbey, Kenichi Umehara, Cordula Stillhart, Knops Noël, Patrick Augustijns, Neil John Parrott
Investigating Tacrolimus Disposition in Paediatric Patients with a Physiologically Based Pharmacokinetic Model Incorporating CYP3A4 Ontogeny, Mechanistic Absorption and Red Blood Cell Binding. Pharmaceutics 15 (9) (2023)
Tejashree Belubbi, Davide Bassani, Cordula Stillhart, Neil John Parrott
Physiologically Based Biopharmaceutics Modeling of Food Effect for Basmisanil: A Retrospective Case Study of the Utility for Formulation Bridging. Pharmaceutics 15 (1) (2023)
Andrea Andrews-Morger, Michael Reutlinger, Neil John Parrott, Andres M Olivares-Morales
A Machine Learning Framework to Improve Rat Clearance Predictions and Inform Physiologically Based Pharmacokinetic Modeling. Molecular pharmaceutics (2023)
Neil John Parrott, Nenad Manevski, Andres M Olivares-Morales
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologically Based Models? A Feasibility Study Based on 12 Development Compounds. Molecular pharmaceutics 19 (11) (2022)
Matthias Van der Veken, Michael Aertsen, Joachim Brouwers, Cordula Stillhart, Neil John Parrott, Patrick Augustijns
Gastrointestinal Fluid Volumes in Pediatrics: A Retrospective MRI Study. Pharmaceutics 14 (9) (2022)
Richard Zang, Aline Barth, Harvey Wong, Jan Marik, Jie Shen, Julie Lade, Kerri Grove, Matthew R Durk, Neil John Parrott, Patrick J Rudewicz, Sylvia Zhao, Tao Wang, Zhengyin Yan, Donglu Zhang
Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation. Journal of medicinal chemistry 65 (13) (2022)